
    
      This is an open-label, non-randomized, dose escalation/expansion phase I study, SHR-1316 is a
      humanized IgG4 monoclonal antibody that binds specifically to human PD-L1.The major aims of
      the study are to define the safety profile of this new drug, and to determine a recommended
      dose and schedule for potential additional trials.
    
  